title: An epidemiologic update on hepatitis C infection in persons living with or at risk of HIV infection.
abstract: Due to shared routes of transmission, coinfection with both human immunodeficiency virus type 1 (HIV-1) and hepatitis C virus (HCV) is relatively common and results in accelerated liver disease, driving morbidity and mortality. Deaths related to HCV now exceed deaths related to HIV in the United States, and co-infected patients bear a significant proportion of that mortality. This burden may be addressed by novel antiviral therapies that promise increased rates of cure or by enhanced access to liver transplantation, but these are costly interventions. Ultimately, the future burden of coinfection is addressed by greater understanding of who is at risk for development of each infection, thus guiding preventive efforts. Key recent reports regarding the US burden of morbidity and mortality due to HCV and groups at risk for coinfection are reviewed, with a focus on recently described HCV occurring among young injection drug users and men who have sex with men. Given the lack of available vaccine against HCV, enhanced detection and surveillance is a vital component of our public health strategy to combat HCV.
authors: Division of Infectious Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. akim1@partners.org
authors: Arthur Y
authors: AY
authors: Kim
authors: Shauna
authors: S
authors: Onofrey
authors: Daniel R
authors: DR
authors: Church
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use; D060085:Coinfection / Q000453:epidemiology* / Q000401:mortality; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000453:epidemiology* / Q000401:mortality; D015497:HIV-1 / Q000302:isolation & purification; D006526:Hepatitis C / Q000150:complications* / Q000453:epidemiology* / Q000401:mortality; D006801:Humans; D016031:Liver Transplantation; D008297:Male; D012307:Risk Factors; D016019:Survival Analysis; D014481:United States / Q000453:epidemiology
chemical_list: D000998:Antiviral Agents
references: N Engl J Med. 2007 Apr 5;356(14):1445-54
references: 17409326
references: MMWR Morb Mortal Wkly Rep. 2012 May 18;61(19):358
references: 22592276
references: Clin Infect Dis. 2012 Jul;55(2):279-90
references: 22491339
references: J Gen Virol. 2011 Oct;92(Pt 10):2227-2236
references: 21775583
references: Ann Intern Med. 2006 May 16;144(10):705-14
references: 16702586
references: Ann Intern Med. 2012 Feb 21;156(4):263-70
references: 22056542
references: Curr Opin HIV AIDS. 2011 Jul;6(4):278-84
references: 21519248
references: J Infect Dis. 2008 Sep 1;198(5):683-6
references: 18627270
references: Clin Infect Dis. 2009 Nov 15;49(10):1605-15
references: 19842982
references: Ann Intern Med. 2012 Feb 21;156(4):271-8
references: 22351712
references: Arch Intern Med. 2006 Aug 14-28;166(15):1632-41
references: 16908797
references: Clin Infect Dis. 2010 Aug 1;51(3):267-73
references: 20575663
references: MMWR Morb Mortal Wkly Rep. 2011 May 6;60(17):537-41
references: 21544042
references: MMWR Morb Mortal Wkly Rep. 2011 Nov 4;60(43):1487-92
references: 22048730
references: J Infect Dis. 2011 Jul 1;204(1):74-83
references: 21628661
references: PLoS One. 2011;6(8):e17502
references: 21826193
references: Hepatology. 2009 Dec;50(6):1750-5
references: 19824079
references: Clin Infect Dis. 2012 Feb 15;54(4):556-9
references: 22156856
references: MMWR Morb Mortal Wkly Rep. 2012 Mar 2;61(8):133-8
references: 22377843
references: Hepatology. 2009 Apr;49(4):1335-74
references: 19330875
references: Ann Intern Med. 2012 Apr 3;156(7):477-82
references: 22473434
references: MMWR Recomm Rep. 2012 Aug 17;61(RR-4):1-32
references: 22895429
references: J Viral Hepat. 2011 Apr;18(4):229-36
references: 21392169
references: J Infect Dis. 2005 Dec 1;192(11):1880-9
references: 16267758